Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-11-14 4:20 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | CITADEL ADVISORS LLC | 2,737,221 3.900% | -1,001,261 (-26.78%) | View |
2024-11-12 6:00 pm Unchanged | 13G | Zentalis Pharmaceuticals Inc. ZNTL | VANGUARD GROUP INC | 4,612,707 6.480% | 0 (Unchanged) | View |
2024-11-06 2:47 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | EVENTIDE ASSET MANAGEMENT LLC | 7,090,108 9.970% | -4,469,867 (-38.67%) | View |
2024-11-04 2:16 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | VANGUARD GROUP INC | 4,612,707 6.480% | -737,751 (-13.79%) | View |
2024-10-18 12:50 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | STATE STREET CORP STT | 1,246,613 1.800% | -3,170,443 (-71.78%) | View |
2024-10-07 11:37 am Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | FMR LLC | 5,075,837 7.138% | -5,261,134 (-50.90%) | View |
2024-02-14 4:57 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | CITADEL ADVISORS LLC | 3,738,482 5.300% | -101,347 (-2.64%) | View |
2024-02-13 7:43 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | Avidity Partners Management LP | 0 0.000% | -5,150,000 (Position Closed) | View |
2024-02-13 5:17 pm Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | VANGUARD GROUP INC | 5,350,458 7.560% | 1,190,309 (+28.61%) | View |
2024-02-09 6:05 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | Capital International Investors | 2,819,664 4.000% | -228,518 (-7.50%) | View |
2024-02-09 10:05 am Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | FMR LLC | 10,336,971 14.607% | 2,427,795 (+30.70%) | View |
2024-02-09 08:40 am Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | WELLINGTON MANAGEMENT GROUP LLP | 68,791 0.100% | -3,549,702 (-98.10%) | View |
2024-01-29 3:26 pm Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | BlackRock Inc. BLK | 4,684,975 6.600% | 1,212,796 (+34.93%) | View |
2024-01-25 07:52 am Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | STATE STREET CORP STT | 4,417,056 6.240% | 1,332,919 (+43.22%) | View |
2023-12-11 5:15 pm Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | EVENTIDE ASSET MANAGEMENT LLC | 11,559,975 16.340% | 3,745,936 (+47.94%) | View |
2023-11-17 5:12 pm Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | CITADEL ADVISORS LLC | 3,839,829 5.400% | 2,335,959 (+155.33%) | View |
2023-10-10 3:40 pm Purchase | 13G | Zentalis Pharmaceuticals Inc. ZNTL | EVENTIDE ASSET MANAGEMENT LLC | 7,814,039 11.070% | 7,814,039 (New Position) | View |
2023-06-20 4:30 pm Purchase | 13D | Zentalis Pharmaceuticals Inc. ZNTL | Matrix Capital Management Company LP | 13,959,973 19.810% | 4,760,000 (+51.74%) | View |
2023-03-09 7:16 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | SUN ANTHONY Y | 360,542 0.600% | -2,631,365 (-87.95%) | View |
2023-02-14 12:38 pm Sale | 13G | Zentalis Pharmaceuticals Inc. ZNTL | PRICE T ROWE ASSOCIATES INC | 2,176,700 3.800% | -2,206,181 (-50.34%) | View |